Rigel Pharmaceuticals RIGL Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue recognized by Product | ||||||
| Delivery of drug supplies, royalties and others | $16.17M-31.6% | $19.05M-6.5% | $22.01M+13.1% | $22.99M+64.2% | $23.63M+87.2% | |
| Discounts and allowances | -$81.8M-18.1% | -$77.98M-19.9% | -$78.62M-36.4% | -$74.46M-44.0% | -$69.24M-51.4% | |
| Gross product sales | $325.16M+40.3% | $309.96M+47.7% | $291.7M+57.2% | $262.4M+56.4% | $231.69M+52.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Rigel Pharmaceuticals break its business down?
- Rigel Pharmaceuticals (RIGL) reports revenue recognized by product across 4 parts — Delivery of drug supplies, royalties and others, Development Milestones, Discounts and allowances and Gross product sales. Each is extracted from the segment footnotes and tracked over time.
- Where does Rigel Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Rigel Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
